Germany Pharmaceuticals and Healthcare Report Q2
2013

Germany Pharmaceuticals and Healthcare Report Q2 2013

BMI View: We continue to believe the Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) legislation - which mandates that cost-effectiveness criteria-based system be used in negotiations of prices of new drugs between drug companies and health insurers - will constrict drug companies' revenue-earning opportunities in Germany. Although we additionally caution that the reform will hamper new drug launches in the country and also lead to further job losses in the industry, Germany will remain one of the largest pharmaceutical markets globally. Headline Expenditure Projections

• Pharmaceuticals: EUR38.65bn (US$49.08bn) in 2012 to EUR37.72bn (US$47.15bn) in 2013; -2.4% in local currency terms and -3.9% in US dollar terms. Local currency forecast slightly lower from Q113, on account of downward pressures on pharmaceutical spending.
• Healthcare: EUR306.00bn (US$388.63bn) in 2012 to EUR313.76bn (US$392.20bn) in 2013; +2.5% in local currency terms and +0.9% in US dollar terms. Local currency forecast slightly lower from Q113, on account of austerity measures.

• Executive Summary
  • SWOT Analysis
  • Germany Pharmaceuticals And Healthcare Industry SWOT
  • Germany Political SWOT
  • Germany Economic SWOT
  • Germany Business Environment SWOT
  • Pharmaceutical Risk/Reward Ratings
    • Table: Western Europe Pharmaceutical Risk/Reward Ratings, Q213
  • Rewards
  • Risks
  • Germany - Market Summary
  • Regulatory Regime
    • Table: BfArM Drug Registration Activity, 2006-10
  • Intellectual Property Regime
  • Pricing Regime
    • Table: Price Build-Up In The German Pharmaceutical Market
  • Pricing Regime Developments
    • Table: Selected AMNOG Drug Assessments
  • Reimbursement Regime
    • Table: Top 10 GKV Selling Drug Brands, 2009-2010 (EURmn)
  • Reimbursement Developments
  • Parallel Imports
  • Industry Developments
  • Epidemiology
  • Healthcare Sector
  • Health Insurance
  • Healthcare Sector Reforms
  • Research & Development
  • Biotechnology Sector
    • Table: Biotechnology Sector, 2008-09
  • Clinical Trials
  • Industry Forecast Scenario
  • Pharmaceutical Market Forecast
    • Table: Germany Pharmaceutical Sales, Historical Data and Forecasts
  • Healthcare Market Forecast
    • Table: Germany Healthcare Expenditure Trends, Historical Data and Forecasts
    • Table: Germany Government Healthcare Expenditure Trends, Historical Data and Forecasts
    • Table: Germany Private Healthcare Expenditure Trends, Historical Data and Forecasts
  • Key Growth Factors - Macroeconomic
    • Table: Germany Long-Term Macroeconomic Forecasts
  • Prescription Drug Market Forecast
    • Table: Retail Pharmaceutical Expenditure, 2003-10 (EURbn)
    • Table: Retail Pharmaceutical Expenditure, 2003-10 (Packages, ms)
    • Table: Retail Pharmaceutical Expenditure, 2003-10 (Average Price per Pack, EUR)
    • Table: Germany Prescription Drug Market Indicators, Historical Data and Forecasts
  • Patented Drug Market Forecast
    • Table: Germany Patented Drug Market Indicators, Historical Data and Forecasts
  • Generic Drug Market Forecast
    • Table: Germany Generics Drug Market Indicators, Historical Data and Forecasts
  • OTC Medicine Market Forecast
    • Table: Germany Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts
  • Pharmaceutical Trade Forecast
    • Table: Germany Pharmaceutical Trade Data And Forecasts (US$mn)
    • Table: Germany Pharmaceutical Trade Data And Forecasts (EURmn)
  • Other Healthcare Data
  • Key Risks To BMI's Forecast Scenario
  • Competitive Landscape
  • Pharmaceutical Industry
    • Table: Pharmaceutical Production, 1990-10
    • Table: Leading German Pharmaceutical Companies
  • Company Developments
  • Wholesale Sector
    • Table: Members of the Association of Pharmaceutical Wholesalers (PHAGRO), 2012
  • Wholesale Sector Developments
  • Retail Sector
  • Online Pharmacies
  • Company Profiles
  • Local Companies
  • Bayer HealthCare
  • Boehringer Ingelheim
  • STADA Arzneimittel
  • Grünenthal
  • Merck KGaA
  • Multinational Companies
  • GlaxoSmithKline (GSK)
  • Pfizer
  • Novartis
  • Sanofi
  • Merck & Co
    • Table: Population By Age Group, 1990-2020 ('000)
    • Table: Population By Age Group, 1990-2020 (% of total)
    • Table: Key Population Ratios, 1990-2020
    • Table: Rural And Urban Population, 1990-2020
  • Glossary
  • BMI Methodology
  • How We Generate Our Pharmaceutical Industry Forecasts
  • Risk/Reward Ratings Methodology
  • Ratings Overview
    • Table: Pharmaceutical Business Environment Indicators
  • Weighting
    • Table: Weighting Of Components
  • Sources